145 related articles for article (PubMed ID: 20117161)
1. Different interaction between tricyclic antidepressants and mecamylamine with the human alpha3beta4 nicotinic acetylcholine receptor ion channel.
Arias HR; Targowska-Duda KM; Feuerbach D; Sullivan CJ; Maciejewski R; Jozwiak K
Neurochem Int; 2010 Mar; 56(4):642-9. PubMed ID: 20117161
[TBL] [Abstract][Full Text] [Related]
2. Tricyclic antidepressants and mecamylamine bind to different sites in the human alpha4beta2 nicotinic receptor ion channel.
Arias HR; Rosenberg A; Targowska-Duda KM; Feuerbach D; Jozwiak K; Moaddel R; Wainer IW
Int J Biochem Cell Biol; 2010 Jun; 42(6):1007-18. PubMed ID: 20223294
[TBL] [Abstract][Full Text] [Related]
3. (-)-Reboxetine inhibits muscle nicotinic acetylcholine receptors by interacting with luminal and non-luminal sites.
Arias HR; Ortells MO; Feuerbach D
Neurochem Int; 2013 Nov; 63(5):423-31. PubMed ID: 23917086
[TBL] [Abstract][Full Text] [Related]
4. Interaction of bupropion with muscle-type nicotinic acetylcholine receptors in different conformational states.
Arias HR; Gumilar F; Rosenberg A; Targowska-Duda KM; Feuerbach D; Jozwiak K; Moaddel R; Wainer IW; Bouzat C
Biochemistry; 2009 Jun; 48(21):4506-18. PubMed ID: 19334677
[TBL] [Abstract][Full Text] [Related]
5. Structure-activity relationship of ibogaine analogs interacting with nicotinic acetylcholine receptors in different conformational states.
Arias HR; Feuerbach D; Targowska-Duda KM; Jozwiak K
Int J Biochem Cell Biol; 2011 Sep; 43(9):1330-9. PubMed ID: 21642011
[TBL] [Abstract][Full Text] [Related]
6. Interaction of selective serotonin reuptake inhibitors with neuronal nicotinic acetylcholine receptors.
Arias HR; Feuerbach D; Targowska-Duda KM; Russell M; Jozwiak K
Biochemistry; 2010 Jul; 49(27):5734-42. PubMed ID: 20527991
[TBL] [Abstract][Full Text] [Related]
7. Interaction of ibogaine with human alpha3beta4-nicotinic acetylcholine receptors in different conformational states.
Arias HR; Rosenberg A; Targowska-Duda KM; Feuerbach D; Yuan XJ; Jozwiak K; Moaddel R; Wainer IW
Int J Biochem Cell Biol; 2010 Sep; 42(9):1525-35. PubMed ID: 20684041
[TBL] [Abstract][Full Text] [Related]
8. Inhibitory mechanisms and binding site location for serotonin selective reuptake inhibitors on nicotinic acetylcholine receptors.
Arias HR; Feuerbach D; Bhumireddy P; Ortells MO
Int J Biochem Cell Biol; 2010 May; 42(5):712-24. PubMed ID: 20079457
[TBL] [Abstract][Full Text] [Related]
9. Functional and structural interaction of (-)-reboxetine with the human α4β2 nicotinic acetylcholine receptor.
Arias HR; Fedorov NB; Benson LC; Lippiello PM; Gatto GJ; Feuerbach D; Ortells MO
J Pharmacol Exp Ther; 2013 Jan; 344(1):113-23. PubMed ID: 23010362
[TBL] [Abstract][Full Text] [Related]
10. Tricyclic antidepressants inhibit hippocampal α7* and α9α10 nicotinic acetylcholine receptors by different mechanisms.
Arias HR; Vázquez-Gómez E; Hernández-Abrego A; Gallino S; Feuerbach D; Ortells MO; Elgoyhen AB; García-Colunga J
Int J Biochem Cell Biol; 2018 Jul; 100():1-10. PubMed ID: 29704625
[TBL] [Abstract][Full Text] [Related]
11. Catharanthine alkaloids are noncompetitive antagonists of muscle-type nicotinic acetylcholine receptors.
Arias HR; Feuerbach D; Targowska-Duda KM; Jozwiak K
Neurochem Int; 2010 Sep; 57(2):153-61. PubMed ID: 20493225
[TBL] [Abstract][Full Text] [Related]
12. Selectivity of (±)-citalopram at nicotinic acetylcholine receptors and different inhibitory mechanisms between habenular α3β4* and α9α10 subtypes.
Arias HR; Jin XT; Gallino S; Peng C; Feuerbach D; García-Colunga J; Elgoyhen AB; Drenan RM; Ortells MO
Neurochem Int; 2019 Dec; 131():104552. PubMed ID: 31545995
[TBL] [Abstract][Full Text] [Related]
13. Coronaridine congeners inhibit human α3β4 nicotinic acetylcholine receptors by interacting with luminal and non-luminal sites.
Arias HR; Targowska-Duda KM; Feuerbach D; Jozwiak K
Int J Biochem Cell Biol; 2015 Aug; 65():81-90. PubMed ID: 26022277
[TBL] [Abstract][Full Text] [Related]
14. Structural and functional interaction of (±)-2-(N-tert-butylamino)-3'-iodo-4'-azidopropiophenone, a photoreactive bupropion derivative, with nicotinic acetylcholine receptors.
Arias HR; Feuerbach D; Targowska-Duda KM; Aggarwal S; Lapinsky DJ; Jozwiak K
Neurochem Int; 2012 Dec; 61(8):1433-41. PubMed ID: 23103524
[TBL] [Abstract][Full Text] [Related]
15. Molecular mechanisms of inhibition of nicotinic acetylcholine receptors by tricyclic antidepressants.
Gumilar F; Arias HR; Spitzmaul G; Bouzat C
Neuropharmacology; 2003 Dec; 45(7):964-76. PubMed ID: 14573389
[TBL] [Abstract][Full Text] [Related]
16. Comparative pharmacology of epibatidine: a potent agonist for neuronal nicotinic acetylcholine receptors.
Gerzanich V; Peng X; Wang F; Wells G; Anand R; Fletcher S; Lindstrom J
Mol Pharmacol; 1995 Oct; 48(4):774-82. PubMed ID: 7476906
[TBL] [Abstract][Full Text] [Related]
17. Receptor protection studies comparing recombinant and native nicotinic receptors: Evidence for a subpopulation of mecamylamine-sensitive native alpha3beta4* nicotinic receptors.
Free RB; Kaser DJ; Boyd RT; McKay DB
Neurosci Lett; 2006 Jan; 392(1-2):135-9. PubMed ID: 16198480
[TBL] [Abstract][Full Text] [Related]
18. Tricyclic antidepressants inhibit homomeric Cys-loop receptors by acting at different conformational states.
Gumilar F; Bouzat C
Eur J Pharmacol; 2008 Apr; 584(1):30-9. PubMed ID: 18314100
[TBL] [Abstract][Full Text] [Related]
19. Conformational mobility of immobilized alpha3beta2, alpha3beta4, alpha4beta2, and alpha4beta4 nicotinic acetylcholine receptors.
Moaddel R; Jozwiak K; Whittington K; Wainer IW
Anal Chem; 2005 Feb; 77(3):895-901. PubMed ID: 15679359
[TBL] [Abstract][Full Text] [Related]
20. Pharmacological and molecular studies on the interaction of varenicline with different nicotinic acetylcholine receptor subtypes. Potential mechanism underlying partial agonism at human α4β2 and α3β4 subtypes.
Arias HR; Feuerbach D; Targowska-Duda K; Kaczor AA; Poso A; Jozwiak K
Biochim Biophys Acta; 2015 Feb; 1848(2):731-41. PubMed ID: 25475645
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
